HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- fluoro- (3- fluorophenyl)- 4- (3- methoxyanilino)quinazoline

structure in first source

Also Known As:

LJJ-10 cpd

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline: 1

Experts

1.	Chen, Kuan-Tin: 1 article (09/2011)
2.	Chiu, Yu-Jen: 1 article (09/2011)
3.	Chuang, Yi-Hsuan: 1 article (09/2011)
4.	Chung, Jing-Gung: 1 article (09/2011)
5.	Hour, Mann-Jen: 1 article (09/2011)
6.	Kuo, Sheng-Chu: 1 article (09/2011)
7.	Lu, Chi-Cheng: 1 article (09/2011)
8.	Tsai, Shih-Chang: 1 article (09/2011)
9.	Yang, Jai-Sing: 1 article (09/2011)

Related Diseases

1.

Osteosarcoma (Osteogenic Sarcoma)

09/01/2011 - "Our previous study demonstrated that 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) possesses potential anticancer activity and exhibits greater antitumor effect than the other quinazoline compounds in human osteogenic sarcoma U-2 OS cells via in vitro screening. "
09/01/2011 - "The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor."

Related Drugs and Biologics

1.	Quinazolines
2.	IGF Type 1 Receptor (IGF 1 Receptor)